Interventions: CagriSema (Cagrilintide B and Semaglutide I), placebo Primary Outcome Measure: Relative change in body weight Time Frame: From baseline (week 0) to week 80 Study Details Source VK2735 for Weight Management Phase 3 (VANQUISH 1) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes
Products are labeled for Research Use Only (RUO) in accordance with applicable FDA guidance and 21 CFR 809.10(c)(2) and are not drugs, dietary supplements, or medical products
Many studies indicate the presence of ellagitannins, which includes chebulinic acid, chebulagic acid, corilagin, emblicanin A and B, geraniin, isocorilagin, pedunculagin, phyllanemblinins AF, and punigluconin [20,23,24,25]
Continuous sources of less-concentrated MP (food containers and drinking water) are also a concern
